Liraglutide is a long-acting GLP-1 receptor agonist developed for the treatment of type 2 diabetes and chronic weight management. MedicaPharma supplies Liraglutide as a GMP-grade active pharmaceutical ingredient (API) suitable for formulation, hospital compounding, clinical research, and commercial manufacturing in regulated markets.
Once-daily dosing supported by extended half-life and albumin binding
Dual benefit for blood glucose control and weight loss
GMP-certified API with full regulatory and logistics support for international distribution
Each batch is delivered under GDP-compliant logistics with full traceability and technical
documentation to support pharmaceutical development and formulation.
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Liraglutide is a long-acting GLP-1 receptor agonist developed for the treatment of type 2 diabetes and chronic weight management.
We are committed to supplying high-quality GMP products with logistics according to GDP regulations.
Liraglutide is an acylated human GLP-1 analogue that binds to the GLP-1 receptor, a Gprotein–
coupled receptor expressed in pancreatic β-cells and the central nervous system.
Upon activation, the receptor stimulates insulin secretion, suppresses glucagon release,
delays gastric emptying, and promotes satiety. This results in lower postprandial glucose
excursions and reduced caloric intake.
Liraglutide is modified with a fatty acid side chain that binds to serum albumin, extending
its plasma half-life and allowing for once-daily subcutaneous dosing. Its resistance to
degradation by dipeptidyl peptidase-4 (DPP-4) enhances its stability in circulation,
providing sustained pharmacologic activity.
Liraglutide has been widely adopted for the treatment of type 2 diabetes and obesity, with
clinical use supported by extensive safety and efficacy data. It significantly lowers blood
glucose levels (HbA1c), supports long-term weight loss, and has shown additional benefits
in cardiovascular risk reduction.
Unlike many antidiabetic agents, Liraglutide offers glycemic control without causing
hypoglycemia when used as monotherapy. It also supports weight reduction, making it an
ideal therapeutic option in patients with metabolic syndrome or comorbid obesity.
MedicaPharma supplies Liraglutide API with complete regulatory documentation, including
Certificates of Analysis, impurity profiles, stability data, and validated analytical methods.
The API is suitable for compounding into injectable solutions or development into pre-filled
syringes and pen devices.
MedicaPharma provides global support with GDP-compliant storage and shipping,
ensuring that Liraglutide API arrives under validated conditions with full batch integrity
maintained.
Liraglutide is generally well tolerated, with the most common side effects being mild to
moderate gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal
discomfort. These effects typically resolve with continued treatment.
Less common but serious risks include pancreatitis and gallbladder-related disorders.
Liraglutide is contraindicated in patients with a personal or family history of medullary
thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. As with all GLP-1
agonists, caution is advised in individuals with pre-existing gastrointestinal conditions.
While the risk of hypoglycemia is low with Liraglutide alone, it may increase when used in
combination with insulin or sulfonylureas. Dose adjustments and close monitoring may be
required in such combinations.
Liraglutide (GMP Grade) is a clinically proven GLP-1 receptor agonist offering safe and
effective treatment for both type 2 diabetes and obesity. Its once-daily dosing, dual
metabolic benefits, and favorable safety profile make it a valuable component of modern
metabolic care.
MedicaPharma offers Liraglutide API manufactured under full GMP compliance,
backed by regulatory documentation, formulation guidance, and reliable global logistics.
Contact MedicaPharma today to request a specification sheet, quotation, or dossier
support for local filings and product development.
